Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK CITY, NY / ACCESSWIRE / September 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Progyny, Inc. (PGNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

PGNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Progyny, Inc. Investment

NEW YORK CITY, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Progyny, Inc. (PGNY) And Encourages Investors to Connect

NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

Progyny, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Progyny, Inc. (PGNY)

NEW YORK CITY, NY / ACCESSWIRE / September 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Progyny, Inc. (PGNY) and Encourages Stockholders to Learn More About the Investigation

Indivior PLC

Moderna

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That May Explode This Month

NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

Did Progyny, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- PGNY

Lost Money on Progyny, Inc.(PGNY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK CITY, NY / ACCESSWIRE / September 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Encourages Progyny, Inc. (PGNY) Investors to Inquire about Securities Investigation

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Progyny, Inc. (“Progyny” or the “Company”) (NASDAQ: PGNY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 18, 2024, Progyny disclosed that it had lost an unnamed “significant client” representing approximately 670,000 members as of June 30, 2024, and comprising 12% of the.

The Law Offices of Frank R. Cruz Announces Investigation of Progyny, Inc. (PGNY) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

Levi & Korsinsky Reminds Progyny, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - PGNY

Lost Money on Progyny, Inc. (PGNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK CITY, NY / ACCESSWIRE / September 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Progyny, Inc. (PGNY) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESSWIRE / September 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Progyny, Inc. (PGNY) And Encourages Stockholders to Reach Out

Progyny Inc.'s stock tumbled 31% Thursday, to put it on track for its biggest-ever one-day decline, after the provider of fertility-care benefits for employers said a “significant” client had terminated its agreement with the company.

Fertility-benefits provider Progyny's stock on track for biggest-ever decline after losing ‘significant' client

Progyny revealed that it's losing a major client. While the client name wasn't disclosed, it accounted for 12% of Progyny's total revenue in the first half of 2024.

Why Progyny Stock Is Crashing Today

Haemonetics

ImmunityBio

Top 3 Health Care Stocks That Are Set To Fly This Quarter

Progyny lowered full-year revenue guidance after seeing an unexpected drop in user utilization rates. The Harris-Walz ticket has put fertility benefits center stage in the upcoming presidential election which makes the stock more volatile in the short-term. Despite current challenges, Progyny's long-term growth thesis remains intact with potential opportunities for expansion in the future.

Progyny: Downgrading As Uncertainties Increase

Revenue of $304.1 million met management's expectations. Adjusted EPS of $0.43 outperformed management's guidance.

Progyny EPS Outperforms, Revenue Dips in Q2

Progyny missed analysts' revenue expectations for the second quarter by a tiny margin. Making matters worse, the company cut sales growth guidance from 15% to 8.5% for 2024.

Why Progyny Stock Dropped Today

Progyny, Inc. (PGNY) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Progyny (PGNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Progyny (PGNY) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.15 per share a year ago.

Progyny (PGNY) Beats Q2 Earnings Estimates

Achieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock

Progyny, Inc. Announces Second Quarter 2024 Results

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Progyny Stock (PGNY)